Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$4M
- +51.1% YoY · +31.0% QoQ
- EPS (diluted)
- −$0.06
- +53.8% YoY · +33.3% QoQ
Source: XBRL data from the Aldeyra Therapeutics, Inc. (ALDX) Q3 2026 10-Q on SEC EDGAR. USD.
Aldeyra Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue: $0, with no approved products and no product sales revenue
- Net loss $3.8M vs $7.7M YoY, loss from operations $4.1M vs $8.0M
- Reproxalap: primary late-stage R&D focus, approximately 30% of quarterly R&D expenses
- Cash $41.0M at September 30, 2026, operating cash use $13.8M year-to-date
- FDA Complete Response Letter and FDRR pending, ADX-2191 retinitis pigmentosa program suspended, AbbVie option unexercised
Risk Factors
- Regulatory risk: 2026 Complete Response Letter triggered FDRR submission on October 26, 2026, with uncertain timing and approval outcome
- Operational risk: Third-party reproxalap manufacturer received Form 483 deficiencies in August 2025, later classified VAI
- Competitive risk: Dry-eye market includes Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye, and Tryptyr
- Financial risk: Nine-month 2026 net loss $12.7 million, accumulated deficit $496.6 million, requiring substantial additional financing
- Legal risk: FDA “radical transparency” policy creates potential Securities Class Action and SEC scrutiny following public Complete Response Letters
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aldeyra Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.